Scientists probe mystery gene's role in heart disease
NCT ID NCT06230406
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a gene called TMEM230 plays a role in atherosclerosis, the buildup of fatty plaques in arteries that can lead to heart attacks and strokes. Researchers will collect blood and artery tissue from 12 adults undergoing vascular surgery. They aim to understand how this gene is turned on or off in diseased arteries, which could eventually lead to new prevention or treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward new targets for preventing or treating atherosclerosis, potentially reducing heart disease and stroke.
- What could go wrong
- This is a very small, early-stage observational study (12 participants) focused on understanding basic biology, not testing a treatment. Results may not lead directly to therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 12 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients coming to the Operative Unit of Vascular Surgery at IRCCS Policlinico San Donato, needing open surgical intervention for arterial and/or venous pathologies
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * adult patients (age \> 18 years) * consent to participate in the study, * patients coming to the Vascular Surgery Unit I of the IRCCS Policlinico San Donato for a vascular pathology of the arterial or venous district worthy of surgical treatment. Exclusion Criteria: * minor patients, * patients who have not given their consent to participate in the study, * patients who have vascular pathologies of the arterial or venous district not susceptible to surgical intervention.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
I.R.C.C.S. Policlinico San Donato
RECRUITINGSan Donato Milanese, Milan, 20097, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hunting the hidden warning signs of heart attacks and strokes
- Heart risk in rheumatoid arthritis: could a blood vessel drug help?
- Can calming inflammation shield the heart?
- Could an old malaria drug shield hearts in kidney disease?
- A new multi-test approach may spot hidden blood vessel damage before symptoms appear
- Can a blood vessel drug beat aspirin at preventing heart attacks in diabetes?